| Drug Name |
Amifostine |
| Drug ID |
BADD_D00102 |
| Description |
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. |
| Indications and Usage |
For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. |
| Marketing Status |
approved; investigational |
| ATC Code |
V03AF05 |
| DrugBank ID |
DB01143
|
| KEGG ID |
D00226
|
| MeSH ID |
D004999
|
| PubChem ID |
2141
|
| TTD Drug ID |
D06CIE
|
| NDC Product Code |
76310-017; 46439-8768; 22568-8865; 60269-275; 61662-0003 |
| UNII |
M487QF2F4V
|
| Synonyms |
Amifostine | APAETP | Aminopropylaminoethylthiophosphoric Acid | S-(N-(3-Aminopropyl)-2-aminoethyl)thiophosphoric Acid | Gammaphos | Ethiofos | Amifostine Disodium Salt | Amifostine Monohydrate | Amifostine Trihydrate | Aminopropylaminoethylthiophosphate | Aminopropyl Aminoethylthiophosphate | Ethyol | NSC-296961 | NSC 296961 | NSC296961 | Amifostine Anhydrous | Ethiofos Anhydrous | WR-2721 | WR 2721 | WR2721 | YM-08310 | YM 08310 | YM08310 | Ethanethiol, 2-((3-aminopropyl)amino)-, dihydrogen phosphate (ester), trihydrate | Amifostine Monohydrochloride |
